Loading
A phase 2 trial of SHR-1826 in non-small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07489716 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 90 participants planned, started 2026-04-29 and due to reach its primary completion in 2028-08. Interventions recorded: SHR-1826.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/